ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method
Journal Title: Turkish Journal of Hematology - Year 2011, Vol 28, Issue 2
Abstract
Objective: Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor imatinib, the development of resistance against imatinib has been observed. The most important mechanisms known to cause resistance are point mutations in the ABL tyrosine kinase and the ATP domain. This study describes the use of denaturing high performance liquid chromatography (dHPLC) as a method to screen for mutations of the ABL gene. Material and Methods: We used the dHPLC based assay for the screening of ABL point mutations. Forty chronic myeloid leukemia (CML) patients who showed resistance to imatinib were screened in parallel by dHPLC and direct sequencing. Results: Nine of the 40 patients (23%) had mutations. Conclusion: dHPLC can be a useful method for pre-screening. Analyzing the mutations and monitoring (high-risk) patients can improve their prognosis and survival rate. dHPLC can potentially become a valuable tool for regular testing of patients in the future.
Authors and Affiliations
Yücel Erbilgin, Suzin Çatal, Ahmet Eşkazan, Özden Hatırnaz, Teoman Soysal, Uğur Özbek
Keywords
Related Articles
- EP ID EP85523
- DOI -
- Views 89
- Downloads 0
Results of the Hematology Laboratory Survey: What has Changed in Eight Years?
.
The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study
Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and M...
Antifosfolipid Antikorları ve Sistemik Skleroderma
Kemik İliği Nekrozundan Gaucher Hastalığı Tanısına Uzun Yol
Hypersegmentation of Granulocytes and Monocytes in a Patient with Primary Myelofibrosis Treated with Hydroxycarbamide
.